NASDAQ:CING Cingulate (CING) Stock Price, News & Analysis → Gold Set to EXPLODE! (From Gold Safe Exchange) (Ad) Free CING Stock Alerts $0.76 -0.12 (-13.62%) (As of 05/10/2024 ET) Add Compare Share Share Today's Range$0.70▼$0.9150-Day Range$0.76▼$1.2452-Week Range$0.70▼$21.80Volume101,385 shsAverage Volume91,378 shsMarket Capitalization$4.60 millionP/E RatioN/ADividend YieldN/APrice Target$8.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get Cingulate alerts: Email Address Cingulate MarketRank™ Stock AnalysisAnalyst RatingHold2.33 Rating ScoreUpside/Downside951.2% Upside$8.00 Price TargetShort InterestHealthy0.20% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.74Based on 9 Articles This WeekInsider TradingAcquiring Shares$1,490 Bought Last QuarterProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.31 out of 5 stars 3.2 Analyst's Opinion Consensus RatingCingulate has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageCingulate has received no research coverage in the past 90 days.Read more about Cingulate's stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.20% of the float of Cingulate has been sold short.Short Interest Ratio / Days to CoverCingulate has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Cingulate has recently decreased by 65.47%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldCingulate does not currently pay a dividend.Dividend GrowthCingulate does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CING. Previous Next 3.2 News and Social Media Coverage News SentimentCingulate has a news sentiment score of 0.74. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.58 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Cingulate this week, compared to 3 articles on an average week.Search Interest11 people have searched for CING on MarketBeat in the last 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cingulate insiders have bought more of their company's stock than they have sold. Specifically, they have bought $1,490.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders38.43% of the stock of Cingulate is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions41.31% of the stock of Cingulate is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Cingulate's insider trading history. Previous Next 0.0 Earnings and Valuation Price to Book Value per Share RatioCingulate has a P/B Ratio of 1.44. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Cingulate's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Weiss Ratings[URGENT] DO NOT Touch These AI Stocks!Artificial intelligence stocks are carrying the market. One of them, Nvidia, recently became the seventh company ever to hit a $1 trillion market cap. But is this AI rally over?Click here for our #1 AI Stock for 2024 and Beyond About Cingulate Stock (NASDAQ:CING)Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, and CTx-1302 (dextroamphetamine) for the treatment of attention-deficit/hyperactivity disorders intended for children, adolescents, and adults. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas.Read More CING Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CING Stock News HeadlinesMay 8, 2024 | investorplace.comCING Stock Earnings: Cingulate Beats EPS for Q1 2024May 8, 2024 | markets.businessinsider.comCingulate Reports First Quarter 2024 Financial Results and Provides Clinical and Business UpdateMay 11, 2024 | Crypto 101 Media (Ad)Tech GIANT’s Plans to Revolutionize Crypto…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. May 8, 2024 | globenewswire.comCingulate Reports First Quarter 2024 Financial Results and Provides Clinical and Business UpdateMay 7, 2024 | msn.comMarijuana Users May Have More EmpathyMay 6, 2024 | msn.com7 Common Misconceptions About OCDMay 2, 2024 | msn.comThe Gift of Experiencing ‘Ego Death’April 30, 2024 | globenewswire.comPeter J. Werth, Successful Pharma Entrepreneur, Philanthropist, Cingulate Investor and Board Member, to be Featured with Chairman and CEO Shane J. Schaffer on Benzinga All Live AccessMay 11, 2024 | Crypto 101 Media (Ad)Tech GIANT’s Plans to Revolutionize Crypto…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. April 24, 2024 | msn.comStress activates brain regions linked to alcohol use disorder differently for women than men, finds studyApril 18, 2024 | msn.comResearchers identify 45 distinct brain connectivity alterations linked to anorexia nervosaApril 16, 2024 | finance.yahoo.comCingulate to Participate in Planet MicroCap Showcase: Vegas 2024April 1, 2024 | bizjournals.comCingulate CEO talks about the pharmaceutical company's road ahead after tough 2023April 1, 2024 | globenewswire.comCingulate Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Clinical and Business UpdateMarch 28, 2024 | yahoo.com5 Easy Secrets of Super Agers That Can Help You Live a Long and Happy LifeMarch 20, 2024 | bizjournals.comCingulate can add $3.5M to latest stock offering as it navigates FDA drug approvalMarch 19, 2024 | globenewswire.comCingulate to Participate in Benzinga All Live Access EventMarch 13, 2024 | msn.comADHD linked to unusual brain connectivity patterns in large-scale neuroimaging studyMarch 13, 2024 | msn.comBreakups Can Actually Change Your Brain Chemistry—Here's HowMarch 12, 2024 | nz.news.yahoo.comWhy you can't focus and what science says can helpMarch 12, 2024 | sg.news.yahoo.comHere's why you can't focus - and science-backed ways to help youMarch 11, 2024 | msn.comSelf-hypnosis is soaring in popularity RN - I tried it after hearing that it could boost your mood and mental health from homeMarch 6, 2024 | globenewswire.comCingulate to Attend DCAT Week 2024 in New York CityFebruary 28, 2024 | bizjournals.comCingulate regains compliance with Nasdaq, maintaining key capital sourceFebruary 25, 2024 | msn.comUsing deep brain stimulation to map dysfunctional brain circuits linked to four disordersFebruary 22, 2024 | foxnews.comNew York woman reports improved mental health after undergoing brain electrode therapyFebruary 22, 2024 | msn.comBrain Pacemaker? New Stimulation Device Tested to Treat Depression Shows Promising ResultsSee More Headlines Receive CING Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cingulate and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today5/11/2024Next Earnings (Estimated)8/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:CING CUSIPN/A CIK1862150 Webwww.cingulate.com Phone913-942-2300FaxN/AEmployees13Year FoundedN/APrice Target and Rating Average Stock Price Target$8.00 High Stock Price Target$8.00 Low Stock Price Target$8.00 Potential Upside/Downside+951.2%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-23,530,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-448.18% Debt Debt-to-Equity RatioN/A Current Ratio1.21 Quick Ratio0.06 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.53 per share Price / Book1.44Miscellaneous Outstanding Shares6,050,000Free Float3,723,000Market Cap$4.60 million OptionableNot Optionable Beta-0.87 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. Shane J. Schaffer Pharm.D. (Age 49)PharmD, CEO & Chairman of the Board Comp: $491.96kDr. Laurie A. Myers M.B.A. (Age 67)Ph.D., Executive VP & COO Comp: $415.17kDr. Matthew N. Brams M.D. (Age 60)Executive VP & Chief Medical Officer Comp: $244.79kMs. Jennifer L. Callahan C.P.A. (Age 53)Senior VP, CFO & Secretary Dr. Raul R. Silva M.D. (Age 66)Executive VP & Chief Science Officer Thomas DaltonVice President of Investor & Public RelationsMore ExecutivesKey CompetitorsFirst Wave BioPharmaNASDAQ:FWBIProtagenic TherapeuticsNASDAQ:PTIXSonnet BioTherapeuticsNASDAQ:SONNGenprexNASDAQ:GNPXTFF PharmaceuticalsNASDAQ:TFFPView All CompetitorsInsidersJennifer L CallahanBought 55 shares on 3/15/2024Total: $1,490.50 ($27.10/share)Jennifer L CallahanBought 250 shares on 9/15/2023Total: $3,350.00 ($13.40/share)Peter J WerthBought 91,157 shares on 8/11/2023Total: $1.00 M ($11.00/share)Jennifer L CallahanBought 100 shares on 5/15/2023Total: $2,020.00 ($20.20/share)Jennifer L CallahanBought 200 shares on 5/12/2023Total: $4,320.00 ($21.60/share)View All Insider Transactions CING Stock Analysis - Frequently Asked Questions Should I buy or sell Cingulate stock right now? 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cingulate in the last twelve months. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" CING shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CING, but not buy additional shares or sell existing shares. View CING analyst ratings or view top-rated stocks. What is Cingulate's stock price target for 2024? 3 equities research analysts have issued twelve-month price objectives for Cingulate's stock. Their CING share price targets range from $8.00 to $8.00. On average, they predict the company's share price to reach $8.00 in the next year. This suggests a possible upside of 951.2% from the stock's current price. View analysts price targets for CING or view top-rated stocks among Wall Street analysts. How have CING shares performed in 2024? Cingulate's stock was trading at $7.65 on January 1st, 2024. Since then, CING shares have decreased by 90.1% and is now trading at $0.7610. View the best growth stocks for 2024 here. When is Cingulate's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 12th 2024. View our CING earnings forecast. When did Cingulate's stock split? Cingulate shares reverse split on Thursday, November 30th 2023. The 1-20 reverse split was announced on Thursday, November 30th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, November 30th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. When did Cingulate IPO? Cingulate (CING) raised $29 million in an initial public offering (IPO) on Wednesday, December 8th 2021. The company issued 4,166,666 shares at a price of $6.00-$8.00 per share. How do I buy shares of Cingulate? Shares of CING stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CING) was last updated on 5/11/2024 by MarketBeat.com Staff From Our PartnersThe Crypto 9-5 Escape PlanCrypto 101 MediaDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldThe A.I. story nobody is telling you (Read ASAP)TradeSmithTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeProtect Your Bank Account Before It’s Too LateWeiss RatingsForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cingulate Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
